Boston, MA 06/19/2014 (wallstreetpr) – Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB), a bio-pharma company that works on development and ascertaining ample commercialization of a myriad of radio-pharmaceutical and precision-diagnostic agents, has received a nod from the US FDA on its supplemental new-drug applications.
Interim CEO Shall Address The Floor
NAVB has also announced that its Interim CEO, Michael Goldberg shall take part in the upcoming 9th Annual JMP Securities Healthcare Conference in New York. The conference is deemed to be held during June 24-25 in the premises of the Westin New York Grand Central, in the New York City. NAVB has been reaffirmed that its presentation shall begin on June 24 (Tuesday) at 02:00 PM EDT.
Discussions On Prospects
The NAVB management has reviewed that despite Lymphoseek sNDA’s nod from the US FDA, the investors have shown keenness in keeping Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) shares; hence, its share price has faltered and downgraded. In this regard, the conference is of sumptuous importance, as the Interim CEO will discuss in details about the prospective diagnostic solutions that are currently being worked upon.
The conference shall be strategic as anticipations are gaining ground that the Interim CEO shall discuss about the little-discussed importances of Lymphoseek (Technetium 99m tilmanocept) in the realm of upbeat radioactive diagnostic imaging that eases the treatment of melanoma, head and neck cancers and breast cancers, and reduces the pangs of sentinel lymph-node biopsy.
Importance Of NAVB’s Pipeline
The upcoming conclave is of strategic importance as it will remain the cynosure of investors’ eyes. Hence, it is of utmost importance that Michael Goldberg doesn’t falter in sharing the insights of the remedial diagnostic solutions in NAVB’s pipeline.
The innovative Lymphoseek sNDA offers effective SLN mapping and helps reduce nodal excision, diminishing the pangs of the surgical processes. The innovation has been duly accepted and Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) has received accolades and positive remarks from a number of Cancer Foundation and NGOs; even patients suffering from this deadly disease have snugged in respite as the Lymphoseek propagates less-invasive curing procedures, ushering sumptuous savings.
It is imperative that Michael Goldberg’s address at the conference would decide whether the share prices would escalate or downgrade further!
